ClinicalTrials.gg
TerminatedNCT01123707Updated Dec 22, 2021Results posted

To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Aripiprazole and Escitalopram in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2021-12-22.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to Sponsor decision; no safety issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Non-randomized
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.

Enrollment
17th of 33
173 · median 173
Started
2010
with 3 others
Phase 3
13 of 33
none open now
Registered
16th of 33
by date
Lead sponsor
9 of 33
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 17th largest by enrollment, is one of 4 that started in 2010, is one of 13 in phase 3, and was the 16th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing aripiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD). Enrollment into the study will be from eligible participants who have completed participation in Protocol 31-08-255 [NCT01111539], 31-08-256 [NCT01111552], or 31-08-263 [NCT01111565] ("rollover" participants).

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder
  • MDD
  • Depression
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who participated in Protocol 31-08-255, 31-08-256, or 31-08-263.

Exclusion criteria

Exclusion Criteria:

  • Participants with a current need for involuntary commitment or who have been hospitalized ≤ 28 days of the Baseline Visit for the current major depressive episode.
  • Participants with a diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder, eating disorder (including anorexia nervosa or bulimia), obsessive compulsive disorder, panic disorder, or posttraumatic stress disorder.
  • Participants with a diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
  • Participants experiencing hallucinations, delusions, or any psychotic symptomatology in the current depressive episode.
  • Participants who have met , Fourth Edition, Text Revision (DSM-IV-TR) criteria for substance abuse in the past 6 months (prior to the Baseline Visit) and/or dependence up to and including the past 12 months (prior to the Baseline Visit), including alcohol and benzodiazepines, but excluding caffeine and nicotine. Participants with two positive drug results for cocaine should be excluded from the study.
  • Participants with hypothyroidism or hyperthyroidism.
  • Participants with a significant risk of committing suicide based on history, investigator's judgment, and/or evaluation based on the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Participants who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders.
  • Participants with insulin-dependent diabetes mellitus (IDDM).
  • Participants with epilepsy or significant history of seizure disorders, except for a single childhood febrile seizure, post-traumatic, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    Prior Aripiprazole/Escitalopram Combination Therapy

    Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the maximum tolerated dose (MTD) by Week 4. Participants who received aripiprazole/escitalopram combination therapy in the double-blind treatment period in previous studies were included in this group.

    Drug: Aripiprazole · Drug: Escitalopram

  • Experimental
    Prior Escitalopram

    Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the double-blind treatment period in previous studies were included in this group.

    Drug: Aripiprazole · Drug: Escitalopram

  • Experimental
    Prior Aripiprazole

    Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received aripiprazole in the double-blind treatment period in previous studies were included in this group.

    Drug: Aripiprazole · Drug: Escitalopram

  • Experimental
    Prior Single-blind Escitalopram

    Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the single-blind treatment period in previous studies were included in this group.

    Drug: Aripiprazole · Drug: Escitalopram

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs), Severe (Grade 3 or Higher) TEAEs, and Discontinuations From the Trial Due to TEAEs

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention. TEAE is defined as an adverse event that started after start of study drug treatment. The Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used to determine the severity wherein Grade 1=mild AE, Grade 2=moderate AE, Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death related to AE.

    Time frame: From first dose up to 30 days post last dose (Up to approximately 40 weeks)

Secondary outcomes

  1. Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score

    The severity of illness was rated using a 7-point CGI-S. CGI-S scores range from 1 to 7, where 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  2. Mean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score

    The severity of illness was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1=not depressed at all, 2=only occasionally depressed to a mild degree, 3=mildly depressed half the time, 4=moderately depressed most of the time, 5=moderately depressed almost all of the time, 6=severely depressed all the time, 7=extremely depressed all the time. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  3. Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: Heart rate \[beats per minute (BPM)\]: \>120, increase \>=15, \<50, decrease \>=15; systolic blood pressure \[millimeter of mercury (mmHg)\]: \>180, increase \>=20, \<90, decrease \>=20; diastolic blood pressure (mmHg): \>105, increase \>=15, \<50, decrease \>=15; orthostatic hypotension: \>=20 mmHg decrease in systolic blood pressure and \>=25 bpm increase in heart rate from supine to sitting; weight (kg) gain: increase \>=7%; or weight loss: decrease \>=7%. Only categories with at least 1 participant with event are reported.

    Time frame: Up to 40 weeks

  4. Mean Change From Baseline in Body Weight

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  5. Mean Change From Baseline in Body Mass Index (BMI)

    BMI= weight(kg)/\[height(m)\^2\].

    Time frame: Baseline, Week 26 and End of the study visit (Week 43 or before)

  6. Number of Participants With Potentially Clinically Significant Laboratory Test Abnormalities

    The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. The categories with at least one participants with abnormal lab value as assessed by the Investigator are reported.

    Time frame: Up to 40 weeks

  7. Mean Change From Baseline in Laboratory Test Results: Prolactin

    Prolactin is a hormone released by the pituitary gland. The prolactin test measures the amount of prolactin in the blood. Prolactin is responsible for the breast growth and milk production during pregnancy and after birth. The normal prolactin levels range from 20 to 25 ng/mL in males and females and 80 to 400 ng/mL in pregnant women. A negative mean change from Baseline indicates reduction in the prolactin levels.

    Time frame: Baseline, Weeks 8, 26, and End of the study visit (Week 43 or before)

  8. Mean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)

    The HbA1c is also known as glycosylated hemoglobin. It is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The mean change in the value of HbA1c was analyzed relative to Baseline. The HbA1c of \<6.0% signifies the normal blood glucose level. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline, Week 8, and End of the study visit (Week 43 or before)

  9. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported. Only categories with at least 1 participant with event are reported.

    Time frame: Up to 40 weeks

  10. Number of Participants With Potentially Clinically Significant Physical Examination Findings

    Time frame: Up to 40 weeks

  11. Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

    The AIMS is a 12-item scale. The first 10 -items are rated from 0 to 4 (0=best, 4=worst). An item score of 0, depending on the item, either means: no abnormal involuntary movement (AIM), or no incapacitation due to AIM, or no awareness of AIM. An item score of 4 either means: severe AIM, or severe incapacitation due to AIM, or being aware of, and severe distress caused by AIM. Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, where a higher score indicates worst outcome. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  12. Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score

    The SAS is a rating scale used to measure extrapyramidal symptoms (EPS). The SAS is a 10-item scale, with each item rated from 1 to 5, with 1 being normal and 5 being the worst. The SAS total score is the sum of ratings for all 10 items, with possible total scores from 10 to 50. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  13. Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score

    The BARS is used to assess the presence and severity of akathisia. This scale consists of 4 items. Only item 4, the 'Global Clinical Assessment of Akathisia', was evaluated for this outcome measure. This item is rated on a 6-point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative mean change from Baseline indicates improvement.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)

  14. Percentage of Participants With Suicidal Ideation in Each Item as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The suicidal ideation compared to Baseline was measured by an increase in suicidal ideation category (1-5 on the C-SSRS) during treatment from the maximum suicidal ideation category at Baseline, or any suicidal ideation during treatment if there is none at Baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (Question 1: wish to be dead; Question 2: non-specific active suicidal thoughts; Question 3: active suicidal ideation with any methods (not plan) without intent to act; Question 4: active suicidal ideation with some intent to act, without specific plan; Question 5: active suicidal ideation with specific plan and intent). A negative change from Baseline indicates improvement. Only those categories and timepoints which have data are reported.

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14 and Last Visit (Week 43 or before)

  15. Mean Change From Baseline in Each Item as Measured by Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI) Subscale Score

    The MGH SFI is a measure of a participant's self-reported sexual functioning. The MGH SFI included 5 questions at the baseline assessment, each addressing experiences over the last month: Question a) interest in sex, Question b) ability to get sexually aroused, Question c) ability to achieve orgasm, Question d) ability to get and maintain an erection, and Question e) overall sexual satisfaction. The MGH SFI at post-baseline visits included one additional question: Question f) overall improvement since the last medication change. Each question/item is rated from 1 through 6. For questions a) through e), a score of 1 indicates 'greater than normal', and 6 'totally absent'. For question f), a score of 1 indicates 'very much improved', and 6 'much worse'. All question scores are analyzed separately. No total or mean score is derived. Each subscale score ranges from 0 to 6, higher scores indicates worsening. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)

  16. Mean Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Overall General Subscore

    The Q-LES-Q-SF is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning with the help of 14 items of total 16 items of the scale. The overall general subscore is obtained using 14 items of the scale. Each item is scored on a 5-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. The raw scores are computed to an overall general subscore of 0 to 100 where lower scores indicate less enjoyment or satisfaction with the activity. A positive change from Baseline indicates improvement.

    Time frame: Baseline, Week 8, 26 and End of the study visit (Week 43 or before)

  17. Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Total Score

    The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The SDS Mean Score of 0 to 10 was calculated as an average of the three item scores. All three item scores needed to be available with the exception of the work/school item score when this item was not applicable. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)

  18. Mean Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score

    The CPFQ is a brief self-rated scale developed to measure cognitive and executive dysfunction in mood and anxiety disorders. It consists of 7 items. The CPFQ total score ranges from 7 to 42, with higher score representing less satisfaction in cognitive and physical functioning. A negative mean change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)

07

Results

Posted Dec 22, 2021
Limitations and caveats
The study was terminated early due to Sponsor decision; no safety issues.

Participant flow

Participants took part in the study at 67 investigative sites in Australia, Estonia, India, Mexico, South Korea, and the United States from 18 November 2010 to 27 September 2011.

Participant flow — Overall Study
MilestonePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Started44413850
Safety sample44413649
Completed0000
Not completed44413850
Withdrew: Lost to follow-up3132
Withdrew: Adverse event5753
Withdrew: Sponsor discontinued study30242540
Withdrew: Participant met withdrawal criteria1101
Withdrew: Investigator withdrew participant0111
Withdrew: Subject withdrew consent4512
Withdrew: Lack of efficacy1210
Withdrew: Subject met exclusion criteria0021

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs), Severe (Grade 3 or Higher) TEAEs, and Discontinuations From the Trial Due to TEAEs

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention. TEAE is defined as an adverse event that started after start of study drug treatment. The Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used to determine the severity wherein Grade 1=mild AE, Grade 2=moderate AE, Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death related to AE.

Time frame:
From first dose up to 30 days post last dose (Up to approximately 40 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs), Severe (Grade 3 or Higher) TEAEs, and Discontinuations From the Trial Due to TEAEs
percentage of participantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
TEAEs54.570.775.067.3
STEAEs2.39.80.00.0
Severe (Grade 3 or Higher) TEAEs0.04.95.62.0
Discontinuations from the Trial due to TEAEs11.417.113.96.1
SecondaryMean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score

The severity of illness was rated using a 7-point CGI-S. CGI-S scores range from 1 to 7, where 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline3.1 ± 1.13.4 ± 1.23.4 ± 0.93.2 ± 0.7
Change from Baseline at Week 1-0.0 ± 0.7-0.2 ± 0.6-0.2 ± 0.6-0.4 ± 0.9
Change from Baseline at Week 2-0.3 ± 0.8-0.3 ± 0.7-0.4 ± 0.6-0.9 ± 0.9
Change from Baseline at Week 4-0.1 ± 0.9-0.5 ± 0.8-0.6 ± 1.0-0.9 ± 0.9
Change from Baseline at Week 6-0.3 ± 0.8-0.5 ± 0.9-0.5 ± 1.1-0.9 ± 0.6
Change from Baseline at Week 8-0.3 ± 0.8-0.5 ± 0.7-0.7 ± 0.9-0.7 ± 1.0
Change from Baseline at Week 14-0.3 ± 1.4-0.6 ± 0.7-1.0 ± 1.2-0.7 ± 1.0
Change from Baseline at Week 20-0.6 ± 0.7-0.3 ± 1.0-1.2 ± 1.1-0.9 ± 0.7
Change from Baseline at Week 26-0.8 ± 0.40.0 ± 0.0-1.0 ± 1.4-1.3 ± 0.8
Change from Baseline at Week 32-1.0 ± NA-2.0 ± NA—-2.0 ± 1.0
Change from Baseline at End of the Study Visit (Week 43 or before)-0.2 ± 1.1-0.6 ± 0.9-0.7 ± 1.1-0.9 ± 1.0
SecondaryMean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score

The severity of illness was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1=not depressed at all, 2=only occasionally depressed to a mild degree, 3=mildly depressed half the time, 4=moderately depressed most of the time, 5=moderately depressed almost all of the time, 6=severely depressed all the time, 7=extremely depressed all the time. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline2.8 ± 1.23.1 ± 1.23.3 ± 1.23.2 ± 1.4
Change from Baseline at Week 10.1 ± 0.8-0.2 ± 0.7-0.2 ± 0.8-0.6 ± 1.0
Change from Baseline at Week 2-0.2 ± 0.9-0.4 ± 0.9-0.4 ± 0.7-1.0 ± 1.2
Change from Baseline at Week 40.0 ± 1.1-0.5 ± 1.0-0.2 ± 1.0-0.9 ± 1.5
Change from Baseline at Week 6-0.1 ± 0.9-0.4 ± 1.3-0.4 ± 0.9-1.1 ± 1.1
Change from Baseline at Week 8-0.2 ± 1.0-0.4 ± 1.0-0.3 ± 0.9-0.9 ± 1.5
Change from Baseline at Week 14-0.1 ± 1.8-0.2 ± 1.2-0.8 ± 1.2-0.9 ± 1.4
Change from Baseline at Week 20-0.4 ± 0.9-0.3 ± 1.2-1.0 ± 1.1-1.3 ± 1.3
Change from Baseline at Week 260.0 ± 1.40.0 ± 0.0-0.6 ± 2.1-1.0 ± 1.1
Change from Baseline at Week 320.0 ± NA-1.0 ± NA—0.0 ± 1.0
Change from Baseline at End of Study Visit (Week 43 or before)-0.1 ± 1.2-0.3 ± 1.2-0.3 ± 1.2-0.9 ± 1.5
SecondaryNumber of Participants With Potentially Clinically Significant Vital Sign Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: Heart rate \[beats per minute (BPM)\]: \>120, increase \>=15, \<50, decrease \>=15; systolic blood pressure \[millimeter of mercury (mmHg)\]: \>180, increase \>=20, \<90, decrease \>=20; diastolic blood pressure (mmHg): \>105, increase \>=15, \<50, decrease \>=15; orthostatic hypotension: \>=20 mmHg decrease in systolic blood pressure and \>=25 bpm increase in heart rate from supine to sitting; weight (kg) gain: increase \>=7%; or weight loss: decrease \>=7%. Only categories with at least 1 participant with event are reported.

Time frame:
Up to 40 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities
ParticipantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Orthostatic Hypotension (mmHg)0010
Weight (kg): Weight Gain >=7%4024
Weight (kg): Weight Loss >=7%5212
SecondaryMean Change From Baseline in Body Weight
Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · kg
Mean Change From Baseline in Body Weight
kgPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline93.0 ± 27.188.3 ± 23.587.0 ± 24.284.7 ± 22.6
Change from Baseline at Week 10.0 ± 2.40.1 ± 1.80.1 ± 1.20.1 ± 1.3
Change from Baseline at Week 20.5 ± 2.60.2 ± 2.10.2 ± 1.40.4 ± 1.5
Change from Baseline at Week 40.3 ± 3.80.4 ± 2.30.4 ± 1.40.2 ± 2.1
Change from Baseline at Week 60.3 ± 4.50.1 ± 2.90.3 ± 2.10.3 ± 2.8
Change from Baseline at Week 8-0.0 ± 5.5-0.5 ± 3.20.4 ± 2.70.2 ± 2.7
Change from Baseline at Week 142.0 ± 5.1-0.9 ± 4.80.7 ± 3.00.6 ± 4.3
Change from Baseline at Week 203.8 ± 2.62.0 ± 1.60.4 ± 5.71.4 ± 1.4
Change from Baseline at Week 265.7 ± NA1.4 ± NA—3.3 ± 0.5
Change from Baseline at Week 32—-3.6 ± NA——
Change from Baseline at Last Visit (Week 43 or before)-0.2 ± 4.70.1 ± 3.10.1 ± 4.01.0 ± 3.7
SecondaryMean Change From Baseline in Body Mass Index (BMI)

BMI= weight(kg)/\[height(m)\^2\].

Time frame:
Baseline, Week 26 and End of the study visit (Week 43 or before)
Reported as:
Mean · kg/m^2
Mean Change From Baseline in Body Mass Index (BMI)
kg/m^2Prior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline33.4 ± 8.630.9 ± 8.131.1 ± 7.630.7 ± 7.4
Change from Baseline at Week 262.3 ± NA0.4 ± NA—1.2 ± 0.2
Change from Baseline at Last Visit (Week 43 or before)0.0 ± 2.5-0.1 ± 1.1-0.1 ± 1.50.4 ± 1.7
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Test Abnormalities

The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. The categories with at least one participants with abnormal lab value as assessed by the Investigator are reported.

Time frame:
Up to 40 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Test Abnormalities
ParticipantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN0100
Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN0100
Bilirubin, Total [mg/deciliter(dL)]: ≥2.00100
Cholesterol, Total, Fasting (mg/dL): ≥24010958
Creatine phosphokinase (CPK), Total (U/L): ≥3 x ULN0101
High-density Lipoprotein (HDL) Cholesterol, Fasting (mg/dL): ≤300021
Low-density Lipoprotein (LDL) Cholesterol, Fasting (mg/dL): ≥1606548
Triglycerides, Fasting (mg/dL): Men ≥160; Women ≥12024161425
Urea Nitrogen (mg/dL); >= 30 mg/dL0010
Uric Acid (mg/dL): Men ≥10.5; Women ≥8.50001
Eosinophils (%): ≥100100
Hematocrit (%): Female ≤32%; Male: ≤37% or 3 point decrease from baseline0110
Hemoglobin (g/dL): Men ≤11.5; Women ≤9.51010
Prolactin [nanograms (ng)/mL]: >1 ULN1110
SecondaryMean Change From Baseline in Laboratory Test Results: Prolactin

Prolactin is a hormone released by the pituitary gland. The prolactin test measures the amount of prolactin in the blood. Prolactin is responsible for the breast growth and milk production during pregnancy and after birth. The normal prolactin levels range from 20 to 25 ng/mL in males and females and 80 to 400 ng/mL in pregnant women. A negative mean change from Baseline indicates reduction in the prolactin levels.

Time frame:
Baseline, Weeks 8, 26, and End of the study visit (Week 43 or before)
Reported as:
Mean · ng/mL
Mean Change From Baseline in Laboratory Test Results: Prolactin
ng/mLPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Mean Change from Baseline at Week 80.52 ± 3.940.31 ± 4.370.62 ± 3.26-1.10 ± 6.88
Mean Change from Baseline at Week 26-0.79 ± NA-2.75 ± NA—-0.75 ± 0.52
Mean Change from Baseline at Week Last Visit (Week 43 or before)0.37 ± 4.371.33 ± 4.710.30 ± 3.25-0.49 ± 5.57
SecondaryMean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)

The HbA1c is also known as glycosylated hemoglobin. It is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The mean change in the value of HbA1c was analyzed relative to Baseline. The HbA1c of \<6.0% signifies the normal blood glucose level. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline, Week 8, and End of the study visit (Week 43 or before)
Reported as:
Mean · percentage of HbA1c
Mean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)
percentage of HbA1cPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Mean Change from Baseline at Week 8—0.30 ± NA——
Mean Change from Baseline at Last Visit (Week 43 or before)-0.30 ± NA0.30 ± NA——
SecondaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported. Only categories with at least 1 participant with event are reported.

Time frame:
Up to 40 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Bradycardia: Decrease of ≥15 bpm1000
Sinus Bradycardia: Decrease of ≥15 bpm1000
Supraventricular Premature Beat: Not Present to Present1010
Ventricular Premature Beat: Not Present to Present0110
1° Atrioventricular Block: Increase of ≥0.05 second0100
Right Bundle-branch Block: Not Present to Present1001
Myocardial Ischemia: Not Present to Present1000
Symmetrical T-wave Inversion: Not Present to Present3100
QTcB1120
QTcF0121
QTcN0110
SecondaryNumber of Participants With Potentially Clinically Significant Physical Examination Findings
Time frame:
Up to 40 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Physical Examination Findings
ParticipantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Number of Participants With Potentially Clinically Significant Physical Examination Findings0000
SecondaryMean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

The AIMS is a 12-item scale. The first 10 -items are rated from 0 to 4 (0=best, 4=worst). An item score of 0, depending on the item, either means: no abnormal involuntary movement (AIM), or no incapacitation due to AIM, or no awareness of AIM. An item score of 4 either means: severe AIM, or severe incapacitation due to AIM, or being aware of, and severe distress caused by AIM. Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, where a higher score indicates worst outcome. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline0.1 ± 0.50.0 ± 0.20.1 ± 0.30.1 ± 0.3
Change from Baseline at Week 4-0.1 ± 0.5-0.0 ± 0.20.0 ± 0.20.2 ± 1.1
Change from Baseline at Week 8-0.1 ± 0.60.0 ± 0.00.0 ± 0.0-0.1 ± 0.4
Change from Baseline at Week 200.0 ± 0.00.0 ± 0.00.0 ± 0.0-0.2 ± 0.6
Change from Baseline at Week 260.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Change from Baseline at Week 320.0 ± NA0.0 ± NA—0.0 ± 0.0
Change from Baseline at End of Study Visit (Week 43 or before)-0.0 ± 0.5-0.0 ± 0.2-0.0 ± 0.4-0.0 ± 0.3
SecondaryMean Change From Baseline in Simpson-Angus Scale (SAS) Total Score

The SAS is a rating scale used to measure extrapyramidal symptoms (EPS). The SAS is a 10-item scale, with each item rated from 1 to 5, with 1 being normal and 5 being the worst. The SAS total score is the sum of ratings for all 10 items, with possible total scores from 10 to 50. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline10.1 ± 0.310.0 ± 0.210.3 ± 0.710.1 ± 0.5
Change from Baseline at Week 40.0 ± 0.30.3 ± 0.70.0 ± 0.70.1 ± 0.5
Change from Baseline at Week 8-0.1 ± 0.40.2 ± 0.5-0.1 ± 0.7-0.0 ± 1.0
Change from Baseline at Week 200.0 ± 0.00.0 ± 0.0-0.3 ± 0.7-0.3 ± 0.6
Change from Baseline at Week 260.0 ± 0.00.0 ± 0.00.0 ± 0.0-0.3 ± 0.8
Change from Baseline at Week 320.0 ± NA0.0 ± NA—-0.7 ± 1.2
Change from Baseline at End of Study Visit (Week 43 or before)0.1 ± 1.10.3 ± 0.80.1 ± 1.1-0.0 ± 0.5
SecondaryMean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score

The BARS is used to assess the presence and severity of akathisia. This scale consists of 4 items. Only item 4, the 'Global Clinical Assessment of Akathisia', was evaluated for this outcome measure. This item is rated on a 6-point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative mean change from Baseline indicates improvement.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline0.2 ± 0.50.1 ± 0.40.4 ± 0.80.1 ± 0.4
Change from Baseline at Week 40.1 ± 0.60.3 ± 0.70.0 ± 0.80.2 ± 0.6
Change from Baseline at Week 8-0.1 ± 0.60.3 ± 1.0-0.1 ± 1.1-0.0 ± 0.6
Change from Baseline at Week 20-0.1 ± 0.4-0.2 ± 0.4-0.4 ± 1.0-0.3 ± 0.9
Change from Baseline at Week 26-0.2 ± 0.4-0.5 ± 0.70.0 ± 0.00.0 ± 0.0
Change from Baseline at Week 320.0 ± NA-1.0 ± NA—-0.3 ± 0.6
Change from Baseline at End of Study Visit (Week 43 or before)-0.0 ± 0.60.3 ± 0.9-0.1 ± 1.10.0 ± 0.5
SecondaryPercentage of Participants With Suicidal Ideation in Each Item as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

The suicidal ideation compared to Baseline was measured by an increase in suicidal ideation category (1-5 on the C-SSRS) during treatment from the maximum suicidal ideation category at Baseline, or any suicidal ideation during treatment if there is none at Baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (Question 1: wish to be dead; Question 2: non-specific active suicidal thoughts; Question 3: active suicidal ideation with any methods (not plan) without intent to act; Question 4: active suicidal ideation with some intent to act, without specific plan; Question 5: active suicidal ideation with specific plan and intent). A negative change from Baseline indicates improvement. Only those categories and timepoints which have data are reported.

Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 14 and Last Visit (Week 43 or before)
Reported as:
Number · percentage of participants
Percentage of Participants With Suicidal Ideation in Each Item as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
percentage of participantsPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Question 1: Baseline0.012.28.34.1
Question 1: Week 10.02.42.80.0
Question 1: Week 20.02.42.80.0
Question 1: Week 42.34.92.80.0
Question 1: Week 62.34.92.80.0
Question 1: Week 80.00.02.82.0
Question 1: Week 142.30.00.00.0
Question 1: Last Visit (Week 43 or before)2.32.45.60.0
Question 2: Week 80.00.00.02.0
Question 2: Week 142.30.00.00.0
Question 2: Last Visit (Week 43 or before)0.00.02.80.0
Question 3: Week 142.30.00.00.0
Question 3: Last Visit (Week 43 or before)0.00.02.80.0
SecondaryMean Change From Baseline in Each Item as Measured by Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI) Subscale Score

The MGH SFI is a measure of a participant's self-reported sexual functioning. The MGH SFI included 5 questions at the baseline assessment, each addressing experiences over the last month: Question a) interest in sex, Question b) ability to get sexually aroused, Question c) ability to achieve orgasm, Question d) ability to get and maintain an erection, and Question e) overall sexual satisfaction. The MGH SFI at post-baseline visits included one additional question: Question f) overall improvement since the last medication change. Each question/item is rated from 1 through 6. For questions a) through e), a score of 1 indicates 'greater than normal', and 6 'totally absent'. For question f), a score of 1 indicates 'very much improved', and 6 'much worse'. All question scores are analyzed separately. No total or mean score is derived. Each subscale score ranges from 0 to 6, higher scores indicates worsening. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Each Item as Measured by Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI) Subscale Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Question a: Baseline4.2 ± 1.73.8 ± 1.54.4 ± 1.43.6 ± 1.6
Question a: Change from Baseline at Week 8-0.1 ± 1.3-0.4 ± 0.9-0.4 ± 0.8-0.3 ± 1.1
Question a: Change from Baseline at Week 26-0.2 ± 0.40.0 ± 0.0-0.4 ± 1.10.0 ± 0.0
Question a: Change from Baseline at End of Study Visit (Week 43 or before)-0.1 ± 1.1-0.3 ± 1.1-0.4 ± 1.2-0.4 ± 1.2
Question b: Baseline3.9 ± 1.73.7 ± 1.54.1 ± 1.43.5 ± 1.6
Question b: Change from Baseline at Week 80.0 ± 0.9-0.2 ± 0.9-0.1 ± 0.9-0.3 ± 0.9
Question b: Change from Baseline at Week 260.2 ± 0.40.0 ± 0.00.0 ± 1.2-0.2 ± 0.4
Question b: Change from Baseline at End of Study Visit (Week 43 or before)0.1 ± 0.8-0.3 ± 1.0-0.2 ± 1.0-0.3 ± 1.1
Question c: Baseline4.0 ± 1.73.8 ± 1.54.1 ± 1.53.5 ± 1.6
Question c: Change from Baseline at Week 8-0.1 ± 1.0-0.3 ± 1.1-0.1 ± 0.9-0.2 ± 0.9
Question c: Change from Baseline at Week 26-0.2 ± 1.10.0 ± 0.0-0.2 ± 1.3-0.2 ± 0.4
Question c: Change from Baseline at End of Study Visit (Week 43 or before)-0.0 ± 1.0-0.4 ± 1.10.0 ± 1.1-0.1 ± 1.1
Question d: Baseline2.5 ± 1.23.0 ± 1.43.6 ± 1.32.9 ± 1.3
Question d: Change from Baseline at Week 80.0 ± 0.00.0 ± 0.5-0.4 ± 0.5-0.2 ± 0.4
Question d: Change from Baseline at Week 260.0 ± NA0.5 ± 0.70.0 ± NA0.0 ± 0.0
Question d: Change from Baseline at End of Study Visit (Week 43 or before)0.1 ± 0.30.0 ± 0.50.1 ± 0.9-0.1 ± 0.8
Question e: Baseline4.2 ± 1.73.9 ± 1.64.4 ± 1.33.7 ± 1.6
Question e: Change from Baseline at Week 8-0.1 ± 1.1-0.3 ± 0.8-0.3 ± 0.8-0.2 ± 1.1
Question e: Change from Baseline at Week 26-0.4 ± 0.50.5 ± 0.7-0.4 ± 1.10.0 ± 0.6
Question e: Change from Baseline at End of Study Visit (Week 43 or before)-0.1 ± 0.9-0.3 ± 1.2-0.3 ± 1.4-0.3 ± 1.4
Question f: Baseline3.3 ± 0.93.5 ± 1.23.4 ± 1.13.6 ± 1.2
Question f: Change from Baseline at Week 80.1 ± 1.1-0.3 ± 1.10.2 ± 1.1-0.7 ± 1.7
Question f: Change from Baseline at Week 26-1.0 ± 0.70.0 ± 0.00.4 ± 1.9-0.8 ± 1.3
Question f: Change from Baseline at End of Study Visit (Week 43 or before)-0.0 ± 1.0-0.2 ± 1.1-0.0 ± 1.6-0.6 ± 1.5
SecondaryMean Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Overall General Subscore

The Q-LES-Q-SF is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning with the help of 14 items of total 16 items of the scale. The overall general subscore is obtained using 14 items of the scale. Each item is scored on a 5-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. The raw scores are computed to an overall general subscore of 0 to 100 where lower scores indicate less enjoyment or satisfaction with the activity. A positive change from Baseline indicates improvement.

Time frame:
Baseline, Week 8, 26 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Overall General Subscore
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline49.4 ± 14.750.2 ± 19.947.9 ± 16.852.2 ± 14.6
Change from Baseline at Week 80.8 ± 10.43.6 ± 11.06.2 ± 9.99.5 ± 13.6
Change from Baseline at Week 260.8 ± 19.6-0.5 ± 2.16.2 ± 22.44.3 ± 17.7
Change from Baseline at End of Study visit (Week 43 or before)1.0 ± 14.15.0 ± 15.44.6 ± 14.310.0 ± 16.5
SecondaryMean Change From Baseline in Sheehan Disability Scale (SDS) Mean Total Score

The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The SDS Mean Score of 0 to 10 was calculated as an average of the three item scores. All three item scores needed to be available with the exception of the work/school item score when this item was not applicable. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Total Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline4.6 ± 2.64.3 ± 2.75.1 ± 2.73.8 ± 2.1
Change from Baseline at Week 8-1.1 ± 2.1-0.8 ± 1.6-2.0 ± 2.4-1.4 ± 1.8
Change from Baseline at Week 26-1.9 ± 1.61.7 ± 2.4-2.6 ± 2.7-0.7 ± 4.6
Change from Baseline at End of Study visit (Week 43 or before)-0.6 ± 2.1-0.5 ± 2.5-1.6 ± 2.8-1.6 ± 2.2
SecondaryMean Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score

The CPFQ is a brief self-rated scale developed to measure cognitive and executive dysfunction in mood and anxiety disorders. It consists of 7 items. The CPFQ total score ranges from 7 to 42, with higher score representing less satisfaction in cognitive and physical functioning. A negative mean change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score
score on a scalePrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Baseline23.0 ± 6.122.1 ± 6.524.4 ± 5.322.0 ± 6.1
Change from Baseline at Week 8-1.3 ± 4.1-1.8 ± 2.6-2.2 ± 3.3-4.8 ± 7.7
Change from Baseline at Week 26-3.8 ± 3.52.0 ± 0.0-2.2 ± 5.6-2.5 ± 6.0
Change from Baseline at End of Study Visit (Week 43 or before)-1.0 ± 4.6-0.2 ± 4.8-2.6 ± 5.0-3.5 ± 7.6

Adverse events

Collected over From first dose of study drug through 30 days post last dose (Up to 40 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Aripiprazole/Escitalopram Combination Therapy0/44 (0%)1/44 (2.3%)18/44 (40.9%)
Prior Escitalopram0/41 (0%)4/41 (9.8%)27/41 (65.9%)
Prior Aripiprazole0/36 (0%)0/36 (0%)33/36 (91.7%)
Prior Single-blind Escitalopram0/49 (0%)0/49 (0%)31/49 (63.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
Gastrointestinal necrosisGastrointestinal disorders0/441/410/360/49
Inguinal hernia, obstructiveGastrointestinal disorders0/441/410/360/49
PancreatitisGastrointestinal disorders0/441/410/360/49
Small intestinal obstructionGastrointestinal disorders0/441/410/360/49
Umbilical hernia, obstructiveGastrointestinal disorders0/441/410/360/49
Bile duct stoneHepatobiliary disorders0/441/410/360/49
Cholecystitis acuteHepatobiliary disorders0/441/410/360/49
CholelithiasisHepatobiliary disorders0/441/410/360/49
Pseudomembranous colitisInfections and infestations0/441/410/360/49
Alanine aminotransferase increasedInvestigations0/441/410/360/49
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPrior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind Escitalopram
NauseaGastrointestinal disorders0/443/417/363/49
AkathisiaNervous system disorders2/444/413/366/49
FatigueGeneral disorders1/440/414/364/49
HeadacheNervous system disorders1/442/412/365/49
SedationNervous system disorders1/442/410/365/49
SomnolenceNervous system disorders4/442/413/362/49
DiarrhoeaGastrointestinal disorders1/440/413/360/49
Weight increasedInvestigations2/441/413/362/49
DizzinessNervous system disorders3/441/413/362/49
Blood glucose increasedInvestigations0/443/410/360/49

Baseline characteristics

Safety Sample included all participants who received in the Treatment Phase at least one dose of aripiprazole/escitalopram combination medication as indicated on the dosing record.

Age, Continuous
Age, Continuous(years)Prior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind EscitalopramTotal
Mean46.1 ± 12.045.8 ± 10.748.6 ± 10.843.4 ± 11.345.8 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Prior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind EscitalopramTotal
Female34252633118
Male1016101652
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind EscitalopramTotal
Hispanic or Latino874524
Not Hispanic or Latino36343243145
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prior Aripiprazole/Escitalopram Combination TherapyPrior EscitalopramPrior AripiprazolePrior Single-blind EscitalopramTotal
American Indian or Alaska Native00000
Asian21115
Native Hawaiian or Other Pacific Islander00000
Black or African American775524
White33313042136
More than one race00000
Unknown or Not Reported22015
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2010 to primary completion in Sep 2011, 10 months.

Results were first posted in Dec 2021, 10 years 2 months after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2010
First posted
May 14, 2010
StartActual
Nov 18, 2010
Primary completionActual
Sep 27, 2011
CompletionActual
Sep 27, 2011
Results delay requested
Aug 17, 2012
Results first posted
Dec 22, 2021
Last update
Dec 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01123707
Responsible party
Sponsor
First posted
May 14, 2010
Start date
Nov 18, 2010
Primary completion
Sep 27, 2011
Completion
Sep 27, 2011
Results posted
Dec 22, 2021
Last update
Dec 22, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Escitalopram

Start the discussion